10Beauty has developed the world's first fully automated manicure machine, The 10, which performs a complete five-step manicure process without human intervention. This technology eliminates traditional labor costs and enhances salon efficiency by providing a quick, high-quality manicure experience through a single-use pod system and a customizable mobile app.

Alyssum Therapeutics is developing AT1965, a small molecule that inhibits CMTR2 in cancer cells to enhance B cell immune responses against solid tumors. This approach targets the recruitment and activation of B cells, which are crucial for improving survival outcomes in patients with advanced malignancies and autoimmune diseases.

AOA Dx is developing GlycoLocate™, a multi-omics platform that utilizes tumor marker gangliosides for early-stage cancer detection, specifically through the AKRIVIS GD™ liquid biopsy test for ovarian cancer. This technology offers high sensitivity and specificity, addressing the critical need for effective early diagnosis in women's health.

BioAesthetics develops biomaterials designed for regenerative medicine applications, focusing on enhancing tissue repair and integration. The company addresses the challenges of biocompatibility and functionality in medical implants, improving patient outcomes and recovery times.

Brixton Biosciences is developing Neural Ice™, a therapeutic injection designed to provide three months or more of pain relief for patients suffering from chronic and acute pain. This investigational treatment, developed at Massachusetts General Hospital, aims to address the significant unmet clinical need for effective pain management solutions.

Cercle provides an AI platform, the Cercle Biomedical Graph, that transforms large-scale healthcare data into real-time, high-quality insights for the women's healthcare sector. This technology enables providers, payors, and pharma companies to enhance business operations and personalize patient care efficiently. The platform leverages LLMs connected to anonymized data to deliver secure, accurate answers to complex industry questions.

Evommune develops novel therapeutics targeting the root causes of chronic inflammatory diseases, utilizing specific antagonists like MRGPRX2 to halt disease progression and alleviate symptoms. The company aims to improve patient outcomes by advancing a clinical-stage pipeline that addresses the debilitating effects of chronic inflammation.

GT Medical Technologies offers GammaTile Therapy, a surgically targeted radiation treatment for patients with operable brain tumors, which is placed at the time of tumor resection. This technology minimizes radiation exposure to healthy tissue, reduces side effects, and ensures 100% treatment compliance, ultimately delaying tumor recurrence and potentially extending patient survival.

Iantrek develops microinterventional surgical technologies, including the CycloPen™ and AlloFlo™, designed for precise cyclodialysis and enhanced uveoscleral outflow in glaucoma treatment. These systems address the challenges of traditional glaucoma surgeries by providing controlled, minimally invasive options that improve patient outcomes and reduce recovery times.

IgGenix uses a proprietary single-cell RNA-sequencing platform, SEQ SIFTER™, to isolate and engineer fully human, high-affinity IgG antibodies that target immunodominant allergens, blocking the allergic cascade. This approach aims to develop safe, injectable therapies for food and environmental allergies, with the first candidate, IGNX001, currently in Phase 1 trials for peanut allergy.

Imperative Care provides a cloud‑based, HIPAA‑compliant platform that aggregates patient data from multiple EHR systems into a single, unified view. It enables real‑time clinical alerts, automated workflow tasks, and customizable analytics dashboards to improve care coordination and reduce administrative overhead for hospitals and large health systems.

inSoma Bio develops recombinant protein-based materials that mimic natural human proteins to create bio-compatible scaffolds for tissue engineering. Their Fractomer biomatrix technology enables the use of a patient's own tissue in reconstructive surgeries, eliminating the need for synthetic implants and enhancing biointegration.

This company develops microbial ecosystems for health using a full-stack technology platform for microbiome drug discovery. Their spatial mapping engine visualizes host-microbiome interactions to generate therapeutic insights. Integrated in-house manufacturing translates these findings into scalable, clinical-stage live biotherapeutic products designed to modulate host immunity.

Mendaera develops the Focalist handheld robotic system designed to enhance needle placement during ultrasound-guided procedures. This technology integrates robotics with real-time imaging to improve clinician confidence and precision in targeting. The system aims to elevate the standard of care for various needle-based interventions.

Nymbl Science offers a physical and cognitive training application that utilizes scientifically proven balance exercises and brain games to reduce the risk of falls among older adults. The platform provides personalized programs that enhance users' physical stability and confidence, enabling them to maintain an active lifestyle.

The startup has developed a non-invasive medical device that measures fetal oxygen levels during labor to enhance maternal and neonatal outcomes. This technology aims to reduce the incidence of birth injuries and unnecessary cesarean sections, ultimately lowering healthcare costs and disparities.

Rejoni develops risk mitigation solutions for gynecological procedures by utilizing advanced data analytics and predictive modeling to identify potential complications. Their technology aims to reduce both immediate and long-term health risks for patients undergoing these procedures.

Reunion Neuroscience is developing RE104, a patented prodrug of 4-OH-DiPT that targets the serotonin 2A receptor to provide fast-acting, short-duration therapeutic effects for postpartum depression and other mental health disorders. The company aims to deliver effective treatment options for patients whose needs are unmet by current antidepressant therapies.

Sequel provides an automated insulin delivery (AID) system that utilizes the Tidepool algorithm for precise insulin measurement and delivery, enabling personalized diabetes management. The company addresses the lack of access to effective insulin therapy for the 63% of insulin-dependent diabetes patients not currently using AID systems.